This review covers the key recent molecular findings in ameloblastoma (AM). However, some statements were questionable and few papers were not included in this review.

Below are some comments:
1. In introduction (p2), the authors used a reference (no. 2) to state AM was the most common benign odontogenic tumor, followed by odontomas.
This statement was not true in most of the papers. The reference (no. 2) has mentioned the results varied between local and referral case populations, with odontomas being most common in the local population. If the authors insist to use this reference, then the bias of this reference should be mentioned.
2. In Wnt pathway and beta-catenin mutations (p5), one recent paper showed one adenoid AM case had beta-catenin and BRAF(V600E) mutation. This should be mentioned and cited.
“Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report. Head Neck Pathol. 2023 Sep;17(3):788-792. doi: 10.1007/s12105-023-01555-9. Epub 2023 Apr 24.”
3. In Targeted therapy, MAPK pathway targeted therapy (p7, line 27), …”no recurrence” during their follow-up.”
Using “recurrence” here is not appropriate. In every cases, the lesions reduced the size significantly, but not completely disappeared. Some cases received surgery and the pathology showed residual tumors. Thus, it might be more appropriate to use “no progression”.
4. In Targeted therapy, MAPK pathway targeted therapy (p7), one recent paper about a clinical study was not included in this review. This should be mentioned and cited. “Neoadjuvant BRAF Targeted Therapy for Ameloblastoma of the Mandible: an Organ Preservation Approach. J Natl Cancer Inst. 2023 Nov 15:djad232. doi: 10.1093/jnci/djad232.”
5. In Targeted therapy, MAPK pathway targeted therapy (p7), one paper has investigated the possible resistance occurred in vitro cell culture experiments and might provide an insight and would be better to included in this review.
“Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma” J. Pers. Med. 2022, 12(1), 77; https://doi.org/10.3390/jpm12010077
6. In Discussion, line 54, “Little evidence exists about mutations affecting TSGs in AM…”. One paper mentioned the TSGs change in AM was not included in this review. This should be mentioned and cited.
“Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol. 2004 Sep;17(9):1062-7.”
7. In Table 1 (p17), the sequence of the papers was better to based on the publication sequence.
8. Provide a table for the BRAF/MEK inhibitor trials - number of patients, specific drugs, length of treatment, adverse effects, etc. This is crucial for understanding the potential for targeted therapy.

1. In page 39 line 3 (Introduction, section of Sonic Hedgehog (SHH) pathways and Smoothed (SMO) gene mutations)
   Larger cohorts of maxillary AMs are needed to confirm this statement and to determine the effect on clinical behaviour".
   Please remove ".